TNX 2600
Alternative Names: TNX-2600Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator University of Kansas
- Developer Tonix Pharmaceuticals Holding Corp; University of Kansas
- Class COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 01 Sep 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA (Parenteral) before September 2020
- 13 Jul 2020 Kansas State University and Tonix Pharmaceuticals agreed to co-develop COVD-19 vaccine